CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 165 enrolled
Drug / intervention
9vHPV Vaccine +1 morebiological
Likely dose
mRNA-1273 Vaccine 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05119855
NCT05119855Phase 3Completed
CompareCT.gov

A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age

Merck Sharp & Dohme LLC·interventional·Posted Nov 15, 2021·Updated Feb 5, 2026

In Brief

A Phase 3 clinical trial evaluating 9vHPV Vaccine and mRNA-1273 Vaccine for Papillomavirus Infections and Coronavirus Disease (COVID-19). Completed, enrolled 165 participants across 38 sites.

Detailed Summary

The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus nonconcomitant administration of 9vHPV and mRNA-1273 vaccines in boys and girls 9 to 11 years of age.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPapillomavirus Infections, Coronavirus Disease (COVID-19)
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedNov 15, 2021
Enrollment StartMar 28, 2022
Primary CompletionDec 12, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.6 years ago

Interventions

9vHPV Vaccinebiological

9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular (IM) injection

mRNA-1273 Vaccinebiological

mRNA-1273 50 mcg dose administered as a 0.25-mL IM injection